Moderna is due to report its second-quarter financial results on Friday ahead of the market open, a day after announcing ...

Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street ...

Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday before the bell. Here’s what to expect.

Analysts have given Moderna a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target ...

US stocks opened under pressure on Friday as investors digested signs of a softening labor market and escalating tariff ...

Friday’s announcement comes after Moderna announced a sweeping headcount reduction earlier this week that will see it slash ...

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

Today, Benzinga 's options scanner spotted 17 uncommon options trades for Moderna. This isn't normal. The overall sentiment of these big-money traders is split between 52% bullish and 35%, bearish.

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize your potential gains.

An explosive phase of growth may be ahead thanks to several potential product launches. A lot can happen in 10 years, and that's good news for a struggling stock like Moderna (NASDAQ: MRNA).